Literature DB >> 16041503

Late sequelae of radiotherapy in adults.

Bidhu K Mohanti1, Manishi Bansal.   

Abstract

Around 3-5 million cancer patients receive radiotherapy worldwide every year. Improved cure rates have led to physicians being confronted with a range of late radiation sequelae, broadly of two types-late effects on normal tissues (LENT) and radiation-induced second malignancies (RISM). These late changes affect the function and quality of life of cancer survivors, increase with increasing radiation dose and show a relationship with time. Overall risks for LENT and RISM are 5-10% and 2-10%, respectively, and the potential benefits of radiotherapy outweigh these risks.

Entities:  

Mesh:

Year:  2005        PMID: 16041503     DOI: 10.1007/s00520-004-0697-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  17 in total

Review 1.  A global strategy for radiotherapy: a WHO consultation.

Authors:  A Porter; A Aref; Z Chodounsky; A Elzawawy; N Manatrakul; T Ngoma; C Orton; E Van't Hooft; K Sikora
Journal:  Clin Oncol (R Coll Radiol)       Date:  1999       Impact factor: 4.126

2.  Radiation carcinogenesis modelling for risk of treatment-related second tumours following radiotherapy.

Authors:  K A Lindsay; E G Wheldon; C Deehan; T E Wheldon
Journal:  Br J Radiol       Date:  2001-06       Impact factor: 3.039

3.  The price of anticancer intervention. Secondary malignancies after radiotherapy.

Authors:  Peter Hoskin
Journal:  Lancet Oncol       Date:  2002-09       Impact factor: 41.316

4.  Radiotherapy-induced second cancers: are we doing enough to protect young patients?

Authors:  R Epstein; I Hanham; R Dale
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

5.  The recording of morbidity related to radiotherapy.

Authors:  S Dische; M F Warburton; D Jones; E Lartigau
Journal:  Radiother Oncol       Date:  1989-10       Impact factor: 6.280

6.  RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system.

Authors:  P Rubin; L S Constine; L F Fajardo; T L Phillips; T H Wasserman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

7.  Cancer prevalence and survivorship issues: analyses of the 1992 National Health Interview Survey.

Authors:  M Hewitt; N Breen; S Devesa
Journal:  J Natl Cancer Inst       Date:  1999-09-01       Impact factor: 13.506

8.  Breast cancer and other second neoplasms after childhood Hodgkin's disease.

Authors:  S Bhatia; L L Robison; O Oberlin; M Greenberg; G Bunin; F Fossati-Bellani; A T Meadows
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

9.  Relationship of leukemia risk to radiation dose following cancer of the uterine corpus.

Authors:  R E Curtis; J D Boice; M Stovall; L Bernstein; E Holowaty; S Karjalainen; F Langmark; P C Nasca; A G Schwartz; M J Schymura
Journal:  J Natl Cancer Inst       Date:  1994-09-07       Impact factor: 13.506

Review 10.  The radiotherapeutic injury--a complex 'wound'.

Authors:  James W Denham; Martin Hauer-Jensen
Journal:  Radiother Oncol       Date:  2002-05       Impact factor: 6.280

View more
  4 in total

Review 1.  Exposing the thyroid to radiation: a review of its current extent, risks, and implications.

Authors:  Bridget Sinnott; Elaine Ron; Arthur B Schneider
Journal:  Endocr Rev       Date:  2010-07-21       Impact factor: 19.871

Review 2.  Adipose-derived stem cells in radiotherapy injury: a new frontier.

Authors:  Lipi Shukla; Wayne A Morrison; Ramin Shayan
Journal:  Front Surg       Date:  2015-01-28

Review 3.  Using PROMs to guide patients and practitioners through the head and neck cancer journey.

Authors:  Simon N Rogers; Brittany Barber
Journal:  Patient Relat Outcome Meas       Date:  2017-11-08

4.  Advanced co-culture 3D breast cancer model for investigation of fibrosis induced by external stimuli: optimization study.

Authors:  Ilya Yakavets; Aurelie Francois; Alice Benoit; Jean-Louis Merlin; Lina Bezdetnaya; Guillaume Vogin
Journal:  Sci Rep       Date:  2020-12-04       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.